aplastic anemia | Page 16 | Aplastic Anemia and MDS International Foundation

aplastic anemia

Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia

RATIONALE: It has been shown that about 30% of patients do not respond to immunosuppressive therapy or experience recurrence, and graft rejection and graft-versus-host-disease (GVHD) decrease event-free survival to 30% to 50% in the alternative donor (matched unrelated, partially matched family member) transplantation. Although an overall and disease free survival of 85% to 100%, can be obtained in allogeneic blood or

Aplastic Anemia

Aplastic anemia is a rare disease in which the bone marrow stops producing enough blood cells. Any blood cells the marrow does make are completely normal, but there are simply not enough of them to serve the body's needs. With prompt and proper care, most patients can be successfully treated.